
In April, the FDA announced National Priority Vouchers, clinical trial authorizations, a Breakthrough Device designation, and other updates on therapeutics, diagnostics, and device-based treatments for psychiatric illness. This roundup highlights some of these actions: mdsc.pe/3P2lA9S

English















